title: Effect of renal function on the pharmacokinetics and pharmacodynamics of trandolapril.
abstract: 1. The pharmacokinetics and pharmacodynamics of a single dose of trandolapril, an angiotensin converting enzyme (ACE) inhibitor with an active metabolite, trandolaprilat, which is in part further metabolised prior to renal elimination, were evaluated in 31 subjects with a wide range of renal function (creatinine clearance 4-112 ml min-1 1.73 m-2). 2. The pharmacokinetics of trandolapril were unaffected by differences in renal function. 3. In contrast, there was a close correlation between the renal clearance (0-96 h) of trandolaprilat and creatinine clearance (r = 0.95, P = 0.0001). The maximum plasma concentration of trandolaprilat, and the area under the concentration curve (0-96 h) correlated inversely with creatinine clearance (r = -0.59, P < 0.001; and r = -0.61, P < 0.001 respectively). 4. Significant changes in plasma trandolaprilat concentrations were seen only in patients with creatinine clearances of 30 ml min-1 1.73 m-2 or less, suggesting that a dose reduction in trandolapril might be advisable in severe renal impairment. 5. However, the majority of parameters of ACE inhibition were unrelated to creatinine clearance, although area under the curve for ACE inhibition (0-336 h) showed a weak negative correlation (r = -0.49, P < 0.01). Similarly, weighted mean changes in blood pressure were not influenced by renal function. 6. Therefore, while the pharmacokinetic parameters of trandolaprilat correlated with creatinine clearance, pharmacodynamic measurements (ACE inhibition and blood pressure changes) in general showed no such relationship, indicating that dose adjustment of ACE inhibitors in renal impairment should be based on pharmacokinetic results only in conjunction with pharmacodynamic data.
authors.affiliation: Western Infirmary, Glasgow, Scotland.
authors.forename: E G
authors.initials: EG
authors.lastname: Bevan
authors.forename: G T
authors.initials: GT
authors.lastname: McInnes
authors.forename: J C
authors.initials: JC
authors.lastname: Aldigier
authors.forename: J J
authors.initials: JJ
authors.lastname: Conte
authors.forename: J P
authors.initials: JP
authors.lastname: Grunfeld
authors.forename: S J
authors.initials: SJ
authors.lastname: Harper
authors.forename: B H
authors.initials: BH
authors.lastname: Meyer
authors.forename: N
authors.initials: N
authors.lastname: Pauly
authors.forename: R
authors.initials: R
authors.lastname: Wilkinson
mesh_terms: D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects*; D003404:Creatinine / Q000097:blood / Q000652:urine; D005260:Female; D006801:Humans; D007211:Indoles / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology; D007668:Kidney / Q000502:physiology* / Q000503:physiopathology; D007676:Kidney Failure, Chronic / Q000503:physiopathology*; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D007211:Indoles; C052035:trandolapril; D003404:Creatinine